Last updated on June 2019

A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis


Brief description of study

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

Detailed Study Description

Approximately 120 subjects will receive apremilast 30 mg BID, after a 5-day titration period, with or without MTX. All subjects will be permitted to take NSAIDs and/or low-dose oral glucocorticoids (prednisone 10 mg/day or equivalent) throughout the study. The NSAIDs and low-dose oral glucocorticoids must be on a stable regimen for at least 4 weeks prior to baseline. MTX ( 25 mg/week) will be permitted if treatment duration is 6 months and on a stable regimen for at least 3 months prior to baseline. In addition, Nonsteroidal anti-inflammatory drug (NSAIDs), and low-dose glucocorticoids must be continued from Day 1 through the Week 24 Visit. Change in doses, increase or decrease, and/or discontinuation will not be allowed, except for safety reasons or for lack of availability. After the Week 24 Visit, the doses of MTX, NSAIDs, or glucocorticoids may be adjusted as clinically required.

Clinical Study Identifier: NCT03783026

Find a site near you

Start Over

Malcom Randall VA Medical Center

Gainesville, FL United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

NYU Langone Medical Center

New York, NY United States
  Connect »

Austin Regional Clinic

Austin, TX United States
  Connect »

Swedish Medical Center

Seattle, WA United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Frederiksberg Hospital

Frederiksberg, Denmark
  Connect »

LLC Medical Center Zdorovaya Semiya

Novosibirsk, Russian Federation
  Connect »

Kantonsspital St. Gallen

St. Gallen, Switzerland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.